The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Vlasova A.S.

West Siberian Institute of Postgraduate Medical Education

Petrov S.A.

West Siberian Institute of Postgraduate Medical Education;
Tyumen Scientific Center of the Siberian Branch of the Russian Academy of Sciences

Renzyak E.V.

West Siberian Institute of Postgraduate Medical Education;
District Clinical Hospital of the Khanty-Mansiysk Autonomous Okrug — Yugra

Neuroprotective therapy for age-related macular degeneration

Authors:

Vlasova A.S., Petrov S.A., Renzyak E.V.

More about the authors

Journal: Russian Annals of Ophthalmology. 2024;140(6): 152‑158

DOI: 10.17116/oftalma2024140061152

Read: 1493 times

Buy for 300₽
Contact the author
Table of contents

NEUROPROTECTIVE THERAPY FOR AGE-RELATED MACULAR DEGENERATION
NEUROPROTECTIVE THERAPY FOR AGE-RELATED MACULAR DEGENERATION

To cite this article:

Vlasova AS, Petrov SA, Renzyak EV. Neuroprotective therapy for age-related macular degeneration. Russian Annals of Ophthalmology. 2024;140(6):152‑158. (In Russ.)
https://doi.org/10.17116/oftalma2024140061152

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
Mana­gement of patients with treatment-resistant neovascular age-related macu­lar dege­neration. Russian Annals of Ophthalmology. 2024;(6):63-68
Neuroprotective therapy of glaucoma. Russian Annals of Ophthalmology. 2025;(1):83-90
Oxidative stress in the pathogenesis of chro­nic headache. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):35-40
Reso­lution of the expert council «Possibilities of neuroprotective therapy in patients with arte­rial hype­rtension and cognitive diso­rders». Russian Journal of Preventive Medi­cine. 2024;(11):85-93
Stroke: current state of the problem. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):7-18
Oxidative stress, ferroptosis, soma­tic muta­tions, antioxidant therapy, and endo­metriosis: a new perspective on the issue. Russian Journal of Human Reproduction. 2024;(6):32-44
Modern aspe­cts of chro­nic cere­bral ischemia pathogenetic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):106-113
Neurocytoprotection adva­nces in repe­rfusion therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12-2):75-88
Arte­rial hype­rtension is an oxidative stress, as a pathogenetic target for the treatment of chro­nic cere­brovascular insu­fficiency. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):84-90
Abstract:

Age-related macular degeneration (AMD) is a chronic multifactorial degenerative eye disease and one of the leading causes of irreversible blindness worldwide. Despite extensive research, there is no consensus on the predominant pathological mechanism leading to photoreceptor death. AMD is associated with molecular and cellular disruptions that ultimately result in photoreceptor degeneration. This review summarizes data from international and Russian studies on the pathophysiological mechanisms underlying the development and progression of photoreceptor degeneration, presents scientific developments in therapeutic correction of these disturbances, and highlights promising avenues for pharmacological retinal neuroprotection that require further validation in clinical studies.

Keywords:

age-related macular degeneration
neuroprotection
retinal protection
peptide bioregulators
antioxidants
ethylmethylhydroxypyridine succinate

Authors:

Vlasova A.S.

West Siberian Institute of Postgraduate Medical Education

Petrov S.A.

West Siberian Institute of Postgraduate Medical Education;
Tyumen Scientific Center of the Siberian Branch of the Russian Academy of Sciences

Renzyak E.V.

West Siberian Institute of Postgraduate Medical Education;
District Clinical Hospital of the Khanty-Mansiysk Autonomous Okrug — Yugra

Received:

28.10.2024

Accepted:

25.11.2024

Close metadata

References:

  1. Pennington KL, DeAngelis MM. Epidemiology of agerelated macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. Eye Vis (Lond). 2016;3:34.  https://doi.org/10.1186/s40662-016-0063-5
  2. Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U. Age-Related Macular Degeneration: A Review. JAMA. 2024;331(2):147-157.  https://doi.org/10.1001/jama.2023.26074
  3. Li JQ, Welchowski T, Schmid M, et al. Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis. Br J Ophthalmol. 2020;104(8):1077-1084. https://doi.org/10.1136/bjophthalmol-2019-314422
  4. Neroev VV. Features of ophthalmological morbidity in the Russian Federation. Belye nochi 2024. Accessed 03.09.2024 (In Russ.). https://igb.ru/docs/%D0%94%D0%BE%D0%BA%D0%BB%D0%B0%D0%B4%20%D0%9D%D0%B5%D1%80%D0%BE%D0%B5%D0%B2%20%D0%92.%D0%92.%20%D0%91%D0%B5%D0%BB%D1%8B%D0%B5%20%D0%BD%D0%BE%D1%87%D0%B8%202024%20%D0%97%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%B5%D0%BC%D0%BE%D1%81%D1%82%D1%8C.pdf
  5. Fursova AZh, Gusarevich OG, Tarasov MS, et al. Age-related macular degeneration and glaucoma. Epidemiological and clinical-pathogenetic aspects of the combined course. Sibirskii nauchnyi meditsinskii zhurnal. 2018;38(5): 83-91 (In Russ.). https://doi.org/10.15372/SSMJ20180514
  6. Derevtsova EA, Khokkanen VM, Zarubina VN. Combination of primary open-angle glaucoma and age-related macular degeneration: how common is it? Tochka zreniya. Vostok — Zapad. 2018;(3):81-83 (In Russ.). https://doi.org/10.25276/2410-1257-2018-81-83
  7. Kuroedov AV, Gapon’ko OV, Gorodnichii VV, et al. Effectiveness and tolerability of the combined use of anti-VEGF agents in clinical practice. Klinicheskaya oftal’mologiya. 2020;20(4):209-215 (In Russ.). https://doi.org/10.32364/2311-7729-2020-20-4-209-215
  8. Song JS, Kim MS, Joo K, et al. Iravitrealanty-vascular endothelial growth factor treatment in patients with neovascular age- related macular degeneration and poor visual acuity. Retina. 2024;44(9):1486-1494. https://doi.org/10.1097/IAE.0000000000004154
  9. Zhuang X, Li M, Mi L, et al. Molecular Responses of Anti-VEGF Therapy in Neovascular Age-Related Macular Degeneration: Integrative Insights From Multi-Omics and Clinical Imaging. Invest Ophthalmol Vis Sci. 2024;65(10):24.  https://doi.org/10.1167/iovs.65.10.24
  10. Edwards M, Lutty GA. Bruch’s Membrane and the Choroid in Age-Related Macular Degeneration. Adv Exp Med Biol. 2021;1256:89-119.  https://doi.org/10.1007/978-3-030-66014-7_4
  11. Sazhnyev Y, Sin TN, Ma A, et al. Choroidal Changes in Rhesus Macaques in Aging and Age-Related Drusen. Invest Ophthalmol Vis Sci. 2023;64(12):44.  https://doi.org/10.1167/iovs.64.12.44
  12. Tuichibaeva DM, Yangieva NR. Epidemiological and clinic- functional aspects the combined age- macular degeneration and glaucoma. Peredovaya oftal’mologiya. 2023;1(1):159-165 (In Russ.). https://doi.org/10.57231/j.ao.2023.1.1.037
  13. Durzhinskaya MKh, Budzinskaya MV. Features of the clinical course of age-related macular degeneration in combination with primary open-angle glaucoma. Sovremennye tekhnologii v oftal’mologii. 2019;1(2):260-263 (In Russ.). https://doi.org/10.25276/2312-4911-2019-1-260-263
  14. Klinicheskie rekomendacii «Makuljarnaja degeneracija vozrastnaja». 2024. Accessed 03.09.2024 (In Russ.). https://cr.minzdrav.gov.ru/recomend/114_3
  15. Abokyi S, To CH, Lam TT, et al. Central Role of Oxidative Stress in Age-Related Macular Degeneration: Evidence from a Review of the Molecular Mechanisms and Animal Models. Oxid Med Cell Longev. 2020;2020:7901270. https://doi.org/10.1155/2020/7901270
  16. Dieguez HH, Romeo HE, Alaimo A, et al. Oxidative stress damage circumscribed to the central temporal retinal pigment epithelium in early experimental non-exudative age-related macular degeneration. Free RadicBiol Med. 2019;131:72-80.  https://doi.org/10.1016/j.freeradbiomed.2018.11.035
  17. Dieguez HH, Romeo HE, Alaimo A, et al. Mitochondrial quality control in non-exudative age-related macular degeneration: From molecular mechanisms to structural and functional recovery. Free RadicBiol Med. 2024;219:17-30.  https://doi.org/10.1016/j.freeradbiomed.2024.03.024
  18. Brown EE, Lewin AS, Ash JD. Mitochondria: Potential Targets for Protection in Age-Related Macular Degeneration. Adv Exp Med Biol. 2018;1074:11-17.  https://doi.org/10.1007/978-3-319-75402-4_2
  19. Mehrzadi S, Hemati K, Reiter RJ, et al. Mitochondrial dysfunction in age-related macular degeneration: melatonin as a potential treatment. Expert Opin Ther Targets. 2020;24(4):359-378.  https://doi.org/10.1080/14728222.2020.1737015
  20. Levin LA. Direct and indirect approaches to neuroprotective therapy of glaucomatous optic neuropathy. Surv Ophthalmol. 1999;43(Suppl 1):98-101. 
  21. Teplov DB. Molecular Biology of Neurodegenerative Diseases Visions for the Future-Part B. Academic Press; 2021.
  22. Kurysheva NI. Neiroprotektsiya i neiroregeneratsiya: perspektivy v lechenii glaukomy: monografiya. Moscow: Avtorskii tirazh; 2013 (In Russ.).
  23. Alekseev IB, Ignat’ev SA, Vorob’eva IV, et al. Lechenie glaukomnoi opticheskoi neiropatii metodom endonazal’nogo elektroforeza Korteksina: uchebno-metodicheskoe posobie. Moscow: RMAPO; 2014 (In Russ.).
  24. Trofimova SV, Maksimov IB, Neroev VV. Regulyatornoe deistvie peptidov setchatki. St. Petersburg: Foliant; 2004 (In Russ.).
  25. Derkach AV, Trofimova SV. Treatment of age-related macular degeneration with a complex of peptide bioregulators. Vrach. 2021;32(5):85-87 (In Russ.). https://doi.org/10.29296/25877305-2021-05-16
  26. Neroev VV, Zaitseva OV, Okhotsimskaya TD, et al. The Effectiveness of Retinalamin Administered by Various Intramuscular Injection Timings in the Treatment of Patients with the Dry Form of Age- Related Macular Degeneration. Rossiiskii oftal’mologicheskii zhurnal. 2016;9(1):39-46 (In Russ.). https://doi.org/10.21516/2072-0076-2016-9-1-39-46
  27. Stavitskaya TV, Egorov EA, Topchieva GV, et al. Comparison of neuroprotective properties of retinalamin and emoxipin. RMZh. Klinicheskaya oftal’mologiya. 2004;5(3):108-111 (In Russ.).
  28. Razumovskii MI, Pavlyuchenko KM, Razumovskaya AM. Long-term results of treatment of dystrophic diseases of the retina with peptide bioregulators. Oftal’mologiya. 2015;12(2):43-47 (In Russ.). https://doi.org/10.18008/1816-5095-2015-2-43-47
  29. Irshad M, Chaudhuri PS. Oxidant-antioxidant system: role and significance in human body. Indian J Exp Biol. 2002;40(11):1233-1239.
  30. Tisi A, Feligioni M, Passacantando M, et al. The Impact of Oxidative Stress on Blood-Retinal Barrier Physiology in Age-Related Macular Degeneration. Cells. 2021;10(1):64.  https://doi.org/10.3390/cells10010064
  31. Maiuolo J, Bulotta RM, Oppedisano F, et al. Potential properties of natural nutraceuticals and antioxidants in age-related eye disorders. Life (Basel). 2022;13(1):77.  https://doi.org/10.3390/life13010077
  32. Egorov VV, Smolyakova GP, Danilova LP. Clinical and pharmacological aspects of neuroprotection of ischemic-hypoxic lesions of the optic nervous system of the eyes. Zdravookhranenie Dal’nego Vostoka. 2014;(4):37-42 (In Russ.).
  33. Shchul’kin AV, Yakusheva EN, Chernykh IV. The distribution of mexidol in the rat’s brain and its subcellular fractions. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2014;114(8):70-73 (In Russ.).
  34. Kirova YuI, Shakova FM, Germanova EL, et al. The effect of Mexidol on cerebral mitochondriogenesis at a young age and during aging. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2020;120(1):62-69 (In Russ.). https://doi.org/10.17116/jnevro202012001162
  35. Shchul’kin AV. Modern ideas about the antihypoxic and antioxidant effects of mexidol. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2018;(12):87-93 (In Russ.). https://doi.org/10.17116/jnevro201811812287
  36. Shchul’kin AV. Effect of mexidol on the development of the phenomenon of the neuronal excitotoxicity in vitro. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2012;112(2):35-39 (In Russ.).
  37. Movsisyan A.B., Oganezova ZhG, Egorov EA. Use and outcomes of antioxidant therapy in ophthalmic practice. Russian Annals of Ophthalmology=Vestnik oftal’mologii. 2022;138(5):126-132 (In Russ.). https://doi.org/10.17116/oftalma2022138051126
  38. Stakhovskaya LV, Shamalov NA, Khasanova DR, et al. Results of a randomized, double-blind, multicenter, placebo-controlled, parallel group study of the effectiveness and safety of Mexidol during long-term sequential therapy in patients in the acute and early recovery periods of hemispheric ischemic stroke (EPICA). Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2017; 117(3-2):55-65 (In Russ.). https://doi.org/10.17116/jnevro20171173255-65
  39. Fedin AI, Zakharov VV, Tanashyan MM, et al. Results of an international multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO). Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova.2021;121(11):7-16 (In Russ.). https://doi.org/10.17116/jnevro20211211117
  40. Egorov EA, Gvetadze AA, Davydova NG. Antioxidant agents in neuroprotection treatment of glaucoma. Russian Annals of Ophthalmology=Vestnik oftal’mologii. 2013;129(2):67-69 (In Russ.).
  41. Mukhamed’yanova ASh, Aznabaev RA. Functional parameters of the organ of vision in patients with pre-inciform stage of age-related macular degeneration and hypertension during treatment with Mexidol. Tochka zreniya. Vostok — Zapad. 2011. Accessed 29.09.2024 (In Russ.). https://eyepress.ru/article/funktsional-nye-pokazateli-organa-zreniya-u-patsientov-s-predistsiformnoy-stadie
  42. Egorov EA, Obruch BV, Oleinik AI, et al. The use of the drug Mexidol in patients with dystrophic diseases of the posterior segment of the eye. Klinicheskaya oftal’mologiya. 2009;10(4):145-148 (In Russ.).
  43. Malyshev VE, Sal’nikova OI. The experience of using the drug “Mexidol” in the complex outpatient treatment of patients with eye diseases of degenerative-dystrophic origin. Bjulleten’ eksperimental’noy biologii i meditsiny. 2006;(1):55-57 (In Russ.).
  44. Malyshev VE, Sal’nikova OI. The use of Mexidol in the treatment of primary open-angle glaucoma. Effektivnaya farmakoterapiya. 2022;18(11):52-56 (In Russ.).
  45. Trieschmann M, Beatty S, Nolan JM, et al. Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin: the LUNA study. Exp Eye Res. 2007;84(4):718-728.  https://doi.org/10.1016/j.exer.2006.12.010
  46. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta-carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001; 119(10):1417-1436. https://doi.org/10.1001/archopht.119.10.1417.
  47. Lutein+zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013;309(19):2005-2015. https://doi.org/10.1001/jama.2013.4997
  48. Eskina EN, Belogurova AV, Gvetadze AA, et al. The use of ophthalmic drugs in the “dry” form of age-related macular degeneration. Russian Annals of Ophthalmology=Vestnik oftal’mologii. 2020;136(4):86-92 (In Russ.). https://doi.org/10.17116/oftalma202013604186
  49. Jaffe GJ, Westby K, Csaky KG, et al. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. Ophthalmology. 2021;128(4):576-586.  https://doi.org/10.1016/j.ophtha.2020.08.027
  50. Boyer DS, Gonzalez VH, Kunimoto DY, et al. Safety and Efficacy of Intravitreal Risuteganib for Non-Exudative AMD: A Multicenter, Phase 2a, Randomized, Clinical Trial. Ophthalmic Surg Lasers Imaging Retina. 2021; 52(6):327-335.  https://doi.org/10.3928/23258160-20210528-05
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.